Caris Life Sciences (CAI) Other Non-Current Liabilities (2024 - 2026)

Caris Life Sciences' Other Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $43.6 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $43.6 million in Q1 2026; TTM through Mar 2026 was $43.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $42.4 million, down 53.75% from the prior year.
• Other Non-Current Liabilities improved to $43.6 million in Q1 2026 per CAI's latest filing, from $42.4 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $91.6 million in Q4 2024 and bottomed at $42.4 million in Q4 2025.
• The 3-year median for Other Non-Current Liabilities is $43.6 million (2026), against an average of $59.2 million.
• Biggest YoY gain for Other Non-Current Liabilities was 53.75% in 2025; the steepest drop was 53.75% in 2025.
• Year by year, Other Non-Current Liabilities stood at $91.6 million in 2024, then sank by 53.75% to $42.4 million in 2025, then climbed by 2.86% to $43.6 million in 2026.
• Per Business Quant, the three latest CAI Other Non-Current Liabilities figures stand at $43.6 million (Q1 2026), $42.4 million (Q4 2025), and $91.6 million (Q4 2024).